Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Myelitis

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    34 result(s) found for: Myelitis. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2014-002335-34 Sponsor Protocol Number: STRiVE Start Date*: 2014-10-30
    Sponsor Name:Guy's and St Thomas NHS Foundation Trust
    Full Title: A multicentre randomiSed controlled TRial of IntraVEnous immunoglobulin (IVIg) versus standard therapy for the treatment of transverse myelitis in adults and children
    Medical condition: Transverse myelitis (TM) (acute, first onset cases), including first presentation of neuromyelitis optica (NMO)
    Disease: Version SOC Term Classification Code Term Level
    17.1 10029205 - Nervous system disorders 10028527 Myelitis transverse PT
    17.1 10029205 - Nervous system disorders 10029322 Neuromyelitis optica PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-000793-20 Sponsor Protocol Number: PNS2008-01 Start Date*: 2008-05-05
    Sponsor Name:Erasmus MC [...]
    1. Erasmus MC
    2.
    Full Title: Sirolimus (Rapamune®) for the treatment of anti-Hu associated paraneoplastic neurological syndromes
    Medical condition: Paraneoplastic Neurological Syndromes associated with anti-Hu antibodies
    Disease: Version SOC Term Classification Code Term Level
    9.1 10014619 Encephalomyelitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-005431-41 Sponsor Protocol Number: BN40900(SA-309JG) Start Date*: 2017-10-16
    Sponsor Name:F. Hoffmann-La Roche Ltd.
    Full Title: A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Satralizumab (SA237) as Monotherapy in Patients With Neuromyelitis Optica (NMO) and...
    Medical condition: Neuromyelitis optica (NMO) and NMO spectrum disorder (MNOSD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10029322 Neuromyelitis optica LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed) RO (Completed) HR (Completed)
    Trial results: View results
    EudraCT Number: 2013-003752-21 Sponsor Protocol Number: BN40898(SA-307JG) Start Date*: 2014-05-19
    Sponsor Name:F. Hoffmann-La Roche Ltd.
    Full Title: A multicenter, randomized, addition to baseline treatment, double-blind, placebo-controlled, Phase 3 study to evaluate the efficacy and safety of Satralizumab (SA237) in patients with neuromyelitis...
    Medical condition: Neuromyelitis optica (NMO) and NMO spectrum disorder (MNOSD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10029322 Neuromyelitis optica LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) IT (Ongoing) PL (Completed) HU (Completed) ES (Ongoing)
    Trial results: View results
    EudraCT Number: 2013-001150-10 Sponsor Protocol Number: ECU-NMO-301 Start Date*: 2013-12-12
    Sponsor Name:Alexion Pharmaceuticals, Inc.
    Full Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTI-CENTER TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF ECULIZUMAB IN PATIENTS WITH RELAPSING NEUROMYELITIS OPTICA (NMO)
    Medical condition: Neuromyelitis Optica
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004852 10029322 Neuromyelitis optica LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) IT (Completed) GB (Prematurely Ended) ES (Completed) AT (Prematurely Ended) CZ (Prematurely Ended) DK (Prematurely Ended) FR (Completed) HR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-000529-30 Sponsor Protocol Number: 33 Start Date*: 2013-11-27
    Sponsor Name:Walton Centre Foundation Trust
    Full Title: A pilot study to assess efficacy of prolonged-Release oral fampridine on ambulation and visual function in Neuromyelitis Optica
    Medical condition: Neuromyelitis optica (NMO)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-004092-39 Sponsor Protocol Number: WN41733 Start Date*: 2022-03-23
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A PHASE III, MULTICENTER, OPEN-LABEL, UNCONTROLLED STUDY TO EVALUATE PHARMACOKINETICS, EFFICACY, SAFETY, TOLERABILITY, AND PHARMACODYNAMICS OF SATRALIZUMAB IN PEDIATRIC PATIENTS WITH AQP4 ANTIBODY ...
    Medical condition: Neuromyelitis Optica Spectrum Disorder (NMOSD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10029322 Neuromyelitis optica LLT
    21.1 10029205 - Nervous system disorders 10077875 Neuromyelitis optica spectrum disorder PT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: FR (Ongoing) IT (Ongoing) PL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-000253-36 Sponsor Protocol Number: CD-IA-MEDI-551-1155 Start Date*: 2014-12-08
    Sponsor Name:MedImmune LLC
    Full Title: A Double-masked, Placebo-controlled Study with Open-label Period to Evaluate the Efficacy and Safety of MEDI-551 in Adult Subjects with Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disord...
    Medical condition: Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorders (NMO/NMOSD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10029322 Neuromyelitis optica LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Prematurely Ended) DE (Prematurely Ended) EE (Prematurely Ended) BG (Completed) PL (Prematurely Ended) ES (Prematurely Ended) HU (Prematurely Ended) GR (Completed) NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-001965-34 Sponsor Protocol Number: oral-CORTEM Start Date*: 2012-11-07
    Sponsor Name:Servicio de Neurología, HU. Germans Trias i Pujol
    Full Title: Multicenter, randomized, double-blind clinical trial to compare the clinical and radiological efficacy of 625 mg vs 1250 mg of oral methylprednisolone in patients with multiple sclerosis in relapse.
    Medical condition: Multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    15.0 10029205 - Nervous system disorders 10028245 Multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-001151-12 Sponsor Protocol Number: ECU-NMO-302 Start Date*: 2013-12-12
    Sponsor Name:Alexion Pharmaceuticals, Inc.
    Full Title: A PHASE III, OPEN-LABEL, EXTENSION TRIAL OF ECU-NMO-301 TO EVALUATE THE SAFETY AND EFFICACY OF ECULIZUMAB IN PATIENTS WITH RELAPSING NEUROMYELITIS OPTICA (NMO)
    Medical condition: Neuromyelitis Optica
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10029322 Neuromyelitis optica LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IT (Ongoing) GB (GB - no longer in EU/EEA) ES (Completed) AT (Completed) CZ (Completed) DK (Completed) FR (Completed) HR (Completed)
    Trial results: View results
    EudraCT Number: 2021-001088-26 Sponsor Protocol Number: MN42928 Start Date*: 2021-12-21
    Sponsor Name:F. HOFFMANN - LA ROCHE LTD.
    Full Title: SAKURABONSAI: CLINICAL, IMAGING AND BIOMARKER OPEN-LABEL STUDY IN NEUROMYELITIS OPTICA SPECTRUM DISORDER (NMOSD) WITH SATRALIZUMAB AS AN INTERVENTION
    Medical condition: Neuromyelitis Optica Spectrum Disorder (NMOSD)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10077875 Neuromyelitis optica spectrum disorder PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended) FR (Completed) DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2017-001327-45 Sponsor Protocol Number: 69HCL17_0226 Start Date*: 2017-09-04
    Sponsor Name:Hospices Civils de Lyon
    Full Title: A pilot study of Ceftobiprole diffusion in bone and joint, in patients with BIJ( bone and joint infection) undergoing hip or knee replacement.
    Medical condition: Bone or joint Infection
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10031252 Osteomyelitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-002741-23 Sponsor Protocol Number: BMH 001 Start Date*: 2008-08-22
    Sponsor Name:Berufsgenossenschaftliche Universitätsklinik Bergmannsheil GmbH
    Full Title: Intra-individual, randomized comparison of the MRI contrast agents Gadovist 1.0 versus Dotarem in imaging the distal lower limb of patients with known or suspicion of osteomyelitis, evaluated in a ...
    Medical condition: Osteomyelitis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10031252 Osteomyelitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-006651-39 Sponsor Protocol Number: 111103 Start Date*: 2008-12-22
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase IV, randomized, open-label, controlled, post-licensure study to evaluate the safety of GlaxoSmithKline Biologicals’ HPV-16/18 L1 VLP AS04 vaccine (Cervarix®) when administered intramuscular...
    Medical condition: No medical condition will be investigated in this study. The study will follow vaccinated females and collect safety data focussing on autoimmune diseases, pregnancy outcomes and SAEs considered to...
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-003528-33 Sponsor Protocol Number: VIB0551.P2.S2.NMO Start Date*: 2022-04-13
    Sponsor Name:Horizon Therapeutics Ireland DAC
    Full Title: An Open-label Multicenter Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Inebilizumab in Pediatric Subjects with Neuromyelitis Optica Spectrum Disorder
    Medical condition: Neuromyelitis optica spectrum disorder (NMOSD; also known as Devic's syndrome and previously known as neuromyelitis optica [NMO])
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10077875 Neuromyelitis optica spectrum disorder PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: PL (Ongoing) SE (Trial now transitioned) NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-003230-42 Sponsor Protocol Number: F13640GE210 Start Date*: 2007-10-08
    Sponsor Name:PIERRE FABRE MEDICAMENT
    Full Title: Study of the analgesic effects of repeated doses of F13640 in spinal cord injury patients with moderate to severe central neuropathic pain. A multinational, multicenter, randomized, double blind, p...
    Medical condition: Central neuropathic pain due to spinal cord injury, based on clinical history, clinical examination and appropriate assessment of patient’s signs and symptoms, according to the International Associ...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10064012 Central pain syndrome LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Completed) FI (Prematurely Ended) ES (Completed) BE (Completed) IT (Prematurely Ended) NL (Prematurely Ended) HU (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-001976-21 Sponsor Protocol Number: GQM01 Start Date*: 2011-10-14
    Sponsor Name:Sanofi Pasteur
    Full Title: Safety and Immunogenicity of a Quadrivalent Influenza Vaccine Administered via the Intramuscular Route in Adult and Elderly Subjects
    Medical condition: Prophylaxis of influenza in subjects from 18 years of age
    Disease: Version SOC Term Classification Code Term Level
    14.0 10021881 - Infections and infestations 10022001 Influenza (epidemic) LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2022-002385-32 Sponsor Protocol Number: APHP211057 Start Date*: 2022-08-31
    Sponsor Name:Assistance Publique – Hôpitaux de Paris (AP-HP)
    Full Title: Immediate versus delayed treatment with azathioprine or rituximab in anti-myelin oligodendrocytes glycoprotein (anti-MOG) antibodies associated acute demyelinating syndromes in children: a randomiz...
    Medical condition: myelin oligodendrocytes glycoprotein antibody associated diseases (MOGAD)
    Disease:
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-003544-39 Sponsor Protocol Number: M3-ABMG Start Date*: 2015-10-21
    Sponsor Name:FIDEC - Fighting Infectious Diseases in Emerging Countries
    Full Title: A Phase 4 study to evaluate the safety and immunogenicity of monovalent oral polio vaccine type 2 in healthy IPV-vaccinated children aged 1 to 5 years in Lithuania
    Medical condition: evaluation of safety of SABIN mOPV2 in healthy IPV-vaccinated children of 1 – 5 years of age (Polio disease)
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004862 10036016 Poliomyelitis NOS LLT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: LT (Completed)
    Trial results: View results
    EudraCT Number: 2017-002264-41 Sponsor Protocol Number: P160932J Start Date*: Information not available in EudraCT
    Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
    Full Title: Etude randomisée multicentrique évaluant l’efficacité et la tolérance de l’infliximab comparativement au Cyclophosphamide dans les formes sévères de maladie de Behçet " Multicenter, randomized, pro...
    Medical condition: Induction Therapy with Anti-TNF vs Cyclophosphamide in severe Behçet disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000017240 10004212 Behcet's disease LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 20 03:47:45 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA